Disruptive Technology: Non-Invasive Assessment of Lesion-Specific Physiology | SCAI

Overview

Join SCAI monthly for the latest emerging technologies in interventional cardiology.   

Learning Objectives

Upon completion of these activities, participants will be able to:

  • Evaluate the benefits of the CCTA + FFRCT pathway for optimizing PCI treatment
  • Review cases that employ CCTA + FFRCT to assess CAD risk and plaque functionality.
  • Discuss how utilizing CCTA + FFRCT might impact your practice.

 


 

Agenda 

  • Benefits of the CCTA+FFRCT Pathway for the Cath Lab
  • Assessing CAD Risk
  • Case-Study: FFRCT as a Disruptive Technology at My Facility

Faculty


 

Accreditation Statement 

The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation 

SCAI designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful Completion

Watch the content and complete the evaluation to obtain credit.


 

Registration

Cost: Free

 


 

Acknowledgment of Commercial Support

This webinar is supported by an unrestricted educational grant from Heartflow.

No in-kind commercial support was received.

 


 

SCAI's Independent Content

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 

SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Education Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer-reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships

All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement

SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations. All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients. SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services. Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.

Events Schedule

Learning opportunities from SCAI for the interventional cardiology team.  

Events

Pakistan Live 2024

SCAI Session in Collaboration with PSIC Inside the Cath Lab: What Every Interventionalist Must Know